Driehaus Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Driehaus Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-555,111	Closed	-$2.41M	–	393
2024 Q3	$2.41M	Sell	555,111 -50,790	-8%	-$276K	0.02%	297
2024 Q2	$2.82M	Hold	605,901	–	–	0.03%	284
2024 Q1	$3.07M	Sell	605,901 -91,068	-13%	-$367K	0.03%	292
2023 Q4	$1.96M	Hold	696,969	–	–	0.02%	295
2023 Q3	$2M	Hold	696,969	–	–	0.03%	306
2023 Q2	$3.52M	Buy	+696,969	New	+$1.42M	0.04%	283
2021 Q2	–	Sell	-360,356	Closed	-$8.74M	–	436
2021 Q1	$8.74M	Sell	360,356 -187,981	-34%	-$5.07M	0.13%	220
2020 Q4	$17.6M	Buy	548,337 +8,252	+2%	+$271K	0.28%	109
2020 Q3	$16.3M	Sell	540,085 -53,448	-9%	-$1.63M	0.34%	86
2020 Q2	$25M	Buy	593,533 +10,517	+2%	+$387K	0.61%	41
2020 Q1	$14.5M	Buy	+583,016	New	+$17.7M	0.49%	58

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Driehaus Capital Management's BDTX Position: Q4 2024 in Review

Driehaus Capital Management sold out of Black Diamond Therapeutics (BDTX) in Q4 2024, closing a stake of 555,111 shares — an estimated $2.41M sold.

Driehaus Capital Management first reported a position in BDTX in Q1 2020 and held it in 11 quarters. The position peaked at $25M in Q2 2020. 87 funds tracked by Wall St. Rank hold BDTX as of Q4 2024.

Driehaus Capital Management reported no remaining Black Diamond Therapeutics position as of Q4 2024 after selling out during the quarter.
Driehaus Capital Management sold 555,111 Black Diamond Therapeutics shares in Q4 2024, an estimated $2.41M.
Driehaus Capital Management first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 11 quarters.
Driehaus Capital Management's Black Diamond Therapeutics position peaked at $25M in Q2 2020.
87 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2024.

Based on Driehaus Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.